Published in J Urban Health on March 01, 2006
Health-state utilities in a prisoner population: a cross-sectional survey. Health Qual Life Outcomes (2009) 0.83
Changes in health-related quality of life following imprisonment in 92 women in England: a three month follow-up study. Int J Equity Health (2011) 0.79
Controversies in and challenges to our understanding of hepatitis C. World J Gastroenterol (2007) 0.75
Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort. PLoS One (2016) 0.75
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis (1987) 174.79
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02
Causes and consequences of comorbidity: a review. J Clin Epidemiol (2001) 5.63
Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology (1998) 3.31
Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology (1999) 2.67
The impact of diagnosis of hepatitis C virus on quality of life. Hepatology (1999) 2.32
Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology (2002) 2.26
Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology (2005) 2.07
Evidence for a cerebral effect of the hepatitis C virus. Lancet (2001) 1.90
Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology (1999) 1.84
Time-limit tests: estimating their reliability and degree of speeding. Psychometrika (1951) 1.83
TNF-alpha opens a paracellular route for HIV-1 invasion across the blood-brain barrier. Mol Med (1997) 1.65
Hepatitis B and C in New South Wales prisons: prevalence and risk factors. Med J Aust (1997) 1.57
The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol (2001) 1.50
Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. Am J Gastroenterol (2001) 1.34
Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol (2002) 1.19
Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology (2004) 1.18
Multiple chronic health problems are negatively associated with health related quality of life (HRQoL) irrespective of age. Qual Life Res (2000) 1.15
Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis (2005) 1.09
A scale for estimating the health status of opioid users. Br J Addict (1991) 1.05
Chronic hepatitis C virus infection: does it really impact health-related quality of life? A study in rural Egypt. Hepatology (2004) 1.04
Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J Hepatol (1999) 1.02
Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. Am J Gastroenterol (2001) 1.02
Seroprevalence of markers for hepatitis B, C and G in male and female prisoners--NSW, 1996. Aust N Z J Public Health (1999) 0.95
Prisoners are at risk for hepatitis C transmission. Eur J Epidemiol (2004) 0.92
Labeling may be an important cause of reduced quality of life in chronic hepatitis C. Am J Gastroenterol (2003) 0.86
Mental disorder in the New South Wales prisoner population. Aust N Z J Psychiatry (2005) 0.82
Perceived quality of life and mental health status of Irish female prisoners. Ir Med J (2002) 0.81
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Relation between HIV viral load and infectiousness: a model-based analysis. Lancet (2008) 5.74
Cancer incidence before and after kidney transplantation. JAMA (2006) 4.77
Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet (2006) 4.45
Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol (2014) 4.31
Mass Drug Administration for Scabies Control in a Population with Endemic Disease. N Engl J Med (2015) 4.06
Unprotected anal intercourse, risk reduction behaviours, and subsequent HIV infection in a cohort of homosexual men. AIDS (2009) 3.61
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology (2008) 3.47
Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res (2009) 3.39
Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol (2013) 3.25
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2013) 3.14
HIV prevention research in a resource-limited setting: the experience of planning a trial in Cambodia. Lancet (2005) 2.83
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76
Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution. J Virol (2006) 2.70
Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (2003) 2.69
Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS (2010) 2.65
Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol (2003) 2.65
Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA (2010) 2.61
Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology (2010) 2.56
Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis (2012) 2.51
Counting the cost: estimating the number of deaths among recently released prisoners in Australia. Med J Aust (2011) 2.49
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. Lancet Infect Dis (2009) 2.43
Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol (2003) 2.42
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol (2012) 2.31
"Serosorting" in casual anal sex of HIV-negative gay men is noteworthy and is increasing in Sydney, Australia. AIDS (2006) 2.26
Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis (2009) 2.24
Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend (2009) 2.20
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. Ann Intern Med (2015) 2.14
Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog (2011) 2.13
ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Hepatology (2014) 2.12
Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology (2009) 2.10
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis (2008) 2.06
A practical approach to evidence-based dentistry: IX: how to appraise and use an article about economic analysis. J Am Dent Assoc (2015) 1.99
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology (2009) 1.99
Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS (2002) 1.98
Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience. Vaccine (2010) 1.91
Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol (2012) 1.90
Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology (2011) 1.89
Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction (2006) 1.87
Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS (2004) 1.85
Lack of comprehension of common prostate cancer terms in an underserved population. J Clin Oncol (2009) 1.82
Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology (2010) 1.80
The effect of English language proficiency on length of stay and in-hospital mortality. J Gen Intern Med (2004) 1.80
Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) (2011) 1.79
The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. Int J Epidemiol (2003) 1.78
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology (2013) 1.77
Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Hepatology (2010) 1.77
Surveillance for newly acquired hepatitis C in Australia. J Gastroenterol Hepatol (2004) 1.77
Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-2010. Pharmacoepidemiol Drug Saf (2011) 1.69
High hepatitis C incidence in new injecting drug users: a policy failure? Aust N Z J Public Health (2007) 1.67
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 1.66
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS (2004) 1.62
Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. J Hepatol (2009) 1.61
Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis (2013) 1.61
Estimation of risk of cancers before occurrence of acquired immunodeficiency syndrome in persons infected with human immunodeficiency virus. Am J Epidemiol (2002) 1.60
Transmission of herpes simplex virus types 1 and 2 in a prospective cohort of HIV-negative gay men: the health in men study. J Infect Dis (2006) 1.59
Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children. J Gastroenterol Hepatol (2004) 1.55
Utility-based Quality of Life measures in Alzheimer's disease. Qual Life Res (2006) 1.55
Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis (2004) 1.54
Coverage with evidence development: the Ontario experience. Int J Technol Assess Health Care (2011) 1.53
Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol (2006) 1.53
Trends in HIV incidence in homosexual men in developed countries. Sex Health (2008) 1.52
Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS (2006) 1.52
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology (2008) 1.52
A randomized controlled trial of a smoking cessation intervention conducted among prisoners. Addiction (2013) 1.51
Anal sexually transmitted infections and risk of HIV infection in homosexual men. J Acquir Immune Defic Syndr (2010) 1.50
Sun exposure may increase risk of prostate cancer in the high UV environment of New South Wales, Australia: a case-control study. Int J Cancer (2012) 1.48
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS (2003) 1.47
Epidemiology of syphilis in Australia: moving toward elimination of infectious syphilis from remote Aboriginal and Torres Strait Islander communities? Med J Aust (2011) 1.46
Epidemic syphilis among homosexually active men in Sydney. Med J Aust (2005) 1.46
Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol (2010) 1.45
Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. J Hepatol (2006) 1.45
Early prevention of pressure ulcers among elderly patients admitted through emergency departments: a cost-effectiveness analysis. Ann Emerg Med (2011) 1.43
Traumatic brain injury rates and sequelae: a comparison of prisoners with a matched community sample in Australia. Brain Inj (2010) 1.42
Health care for people with intellectual disability. Med J Aust (2008) 1.40
Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study. Int J Epidemiol (2012) 1.39
Acute appendicitis in young children: cost-effectiveness of US versus CT in diagnosis--a Markov decision analytic model. Radiology (2008) 1.39
High rates of sexually transmitted infections in HIV positive homosexual men: data from two community based cohorts. Sex Transm Infect (2007) 1.39
Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis (2013) 1.38
Highly endemic hepatitis B infection in rural Vietnam. J Gastroenterol Hepatol (2007) 1.38
Lowering Australia's defence against infectious diseases. Med J Aust (2010) 1.38
Variable uptake of recommended interventions to reduce mother-to-child transmission of HIV in Australia, 1982-2005. Med J Aust (2008) 1.37
Circumcision and risk of HIV infection in Australian homosexual men. AIDS (2009) 1.37
Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis (2005) 1.36
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med (2011) 1.36
Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia. Sex Transm Infect (2009) 1.35
Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol (2007) 1.35
Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. J Clin Oncol (2010) 1.34